RU2006132735A - Терапевтические частицы фосфата кальция и способы их получения и применения - Google Patents

Терапевтические частицы фосфата кальция и способы их получения и применения Download PDF

Info

Publication number
RU2006132735A
RU2006132735A RU2006132735/15A RU2006132735A RU2006132735A RU 2006132735 A RU2006132735 A RU 2006132735A RU 2006132735/15 A RU2006132735/15 A RU 2006132735/15A RU 2006132735 A RU2006132735 A RU 2006132735A RU 2006132735 A RU2006132735 A RU 2006132735A
Authority
RU
Russia
Prior art keywords
particles
biologically active
particles according
aqueous solution
group
Prior art date
Application number
RU2006132735/15A
Other languages
English (en)
Inventor
Уиль м В. ЛИ (US)
Уильям В. ЛИ
Original Assignee
Нод Фармасьютикалз, Инк. (Us)
Нод Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нод Фармасьютикалз, Инк. (Us), Нод Фармасьютикалз, Инк. filed Critical Нод Фармасьютикалз, Инк. (Us)
Publication of RU2006132735A publication Critical patent/RU2006132735A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (21)

1. Частицы, включающие
a) сердцевину из наночастицы фосфата кальция;
b) биологически активную макромолекулу, инкапсулированную в сердцевине частиц; и
c) поверхностно-модифицирующее средство, включающее желчную кислоту, инкапсулированную в сердцевине частиц.
2. Частицы по п.1, у которых диаметр сердцевины частиц составляет менее 300 нм.
3. Частицы по п.1, у которых желчная кислота выбрана из группы, состоящей из холата, дезоксихолата, таурохолата, гликохолата, тауродезоксихолата, урсодезоксихолата, тауроурсодезоксихолата и хенодезоксихолата.
4. Частицы по п.1, которые дополнительно включают энтеросолюбильное покрытие.
5. Частицы по п.1, у которых биологически активная макромолекула выбрана из группы, состоящей из белка, полипептида, полисахарида, нуклеиновой кислоты, полинуклеотида, липида и углевода.
6. Частицы по п.5, у которых белок или полипептид выбран из группы, состоящей из инсулина, эритропоэтина, интерферона, гормона роста и колониестимулирующего фактора гранулоцитов (G-CSF).
7. Частицы по п.4, у которых биологически активная макромолекула выбрана из группы, состоящей из инсулина, эритропоэтина, интерферона, гормона роста и G-CSF.
8. Частицы по п.1, у которых биологически активная макромолекула представляет собой аллерген, выбранный из группы, состоящей из домашней пыли мышей, перхоти животных, плесени, пыльцы, амброзии, латекса, осиного яда и аллергенов из насекомых, а также их комбинаций.
9. Частицы по п.1, которые приспособлены в виде аэрозоля.
10. Частицы по п.1, которые приспособлены для доставки биологически активных макромолекул на поверхность слизистой оболочки.
11. Частицы по п.1, которые приспособлены для доставки биологически активных макромолекул на глазную поверхность субъекта, нуждающегося в них для лечения глазного заболевания.
12. Фармацевтическая композиция, включающая частицы по п.1 и фармацевтически приемлемый носитель.
13. Фармацевтическая композиция, включающая частицы по п.4 и фармацевтически приемлемый носитель.
14. Фармацевтическая композиция, включающая частицы по п.7 и фармацевтически приемлемый носитель.
15. Способ получения одной или нескольких частиц фосфата кальция, который включает
a) контактирование водного раствора соли кальция с водным раствором соли фосфата в присутствии поверхностно-модифицирующего средства, включающего желчную кислоту;
b) перемешивание раствора до тех пор, пока не будут получены частицы фосфата кальция нужного размера; и
c) выделение частиц.
16. Способ по п.15, в котором концентрация соли кальция составляет от 5 до 200 мМ.
17. Способ по п.15, в котором концентрация фосфата составляет от 5 до 200 мМ.
18. Способ по п.15, в котором частицы имеют диаметр менее 300 нм.
19. Способ по п.15, дополнительно включающий добавление биологически активной макромолекулы в водный раствор соли фосфата или водный раствор соли кальция перед контактированием водного раствора соли кальция с водным раствором соли фосфата в присутствии поверхностно-модифицирующего средства, включающего желчную кислоту, при этом происходит совместная кристаллизация частиц фосфата кальция с макромолекулами.
20. Способ по п.14, в котором желчная кислота выбрана из группы, состоящей из холата, дезоксихолата, таурохолата, гликохолата, тауродезоксихолата, урсодезоксихолата, тауроурсодезоксихолата и хенодезоксихолата.
21. Способ лечения субъекта, нуждающегося в биологически активной макромолекуле, который включает введение субъекту фармацевтической композиции по п.1.
RU2006132735/15A 2004-02-13 2005-02-11 Терапевтические частицы фосфата кальция и способы их получения и применения RU2006132735A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54469304P 2004-02-13 2004-02-13
US60/544,693 2004-02-13

Publications (1)

Publication Number Publication Date
RU2006132735A true RU2006132735A (ru) 2008-03-20

Family

ID=34919321

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006132735/15A RU2006132735A (ru) 2004-02-13 2005-02-11 Терапевтические частицы фосфата кальция и способы их получения и применения

Country Status (14)

Country Link
US (1) US7651694B2 (ru)
EP (1) EP1720520B1 (ru)
JP (1) JP5103022B2 (ru)
KR (1) KR20070002014A (ru)
CN (1) CN1993113B (ru)
AT (1) ATE470433T1 (ru)
AU (1) AU2005219372A1 (ru)
BR (1) BRPI0507680A (ru)
CA (1) CA2555921A1 (ru)
DE (1) DE602005021756D1 (ru)
ES (1) ES2344303T3 (ru)
MX (1) MXPA06009222A (ru)
RU (1) RU2006132735A (ru)
WO (1) WO2005084637A2 (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031287A (zh) * 2004-03-02 2007-09-05 麻省理工学院 纳米细胞药物递送系统
JP5457680B2 (ja) 2006-01-24 2014-04-02 アンサン バイオファーマ，インコーポレイテッド 高分子マイクロスフェアの調製技術
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009038591A1 (en) * 2007-09-17 2009-03-26 Yale University Bile salt colloids and methods of making and using thereof
US20100283570A1 (en) * 2007-11-14 2010-11-11 Lavoie Adrien R Nano-encapsulated magnetic particle composite layers for integrated silicon voltage regulators
WO2009135190A2 (en) * 2008-05-01 2009-11-05 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
KR101689635B1 (ko) 2008-09-23 2016-12-26 라보라토리 스킨 케어, 인크. 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도
US9901551B2 (en) * 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US20100285611A1 (en) * 2009-05-06 2010-11-11 Ostafin Agnes E Photobleaching resistant ph sensitive dye nanoreactors with dual wavelength emission
US8445002B2 (en) * 2009-05-06 2013-05-21 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
GB0909183D0 (en) * 2009-05-28 2009-07-08 Bedi Kathryn J Coating method
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
EP2533753B1 (en) 2009-11-10 2022-07-06 Laboratory Skin Care, Inc. Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles, and methods of making and using the same
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
KR20140114736A (ko) 2010-10-19 2014-09-29 엘셀릭스 테라퓨틱스 인코포레이티드 화학감각 수용체 리간드-기반 요법
CN103781485A (zh) 2011-01-19 2014-05-07 护肤品实验室有限公司 局部米诺环素组合物及其使用方法
CO6540157A1 (es) * 2011-04-15 2012-10-16 Univ Antioquia Proceso continuo para la elaboracion de nanoparticulas y nanoparticulas obtenidas mediante dicho proceso
CN104039312A (zh) * 2011-08-16 2014-09-10 实验室护肤股份有限公司 细干颗粒腺苷组合物和包括其的局部制剂
EP2755659A2 (en) * 2011-09-13 2014-07-23 Altacor Limited Pharmaceutical nanoparticle compositions
CN102580109B (zh) * 2012-03-02 2013-11-06 河南师范大学 一种抗癌药物载体及其制备方法
US20140099380A1 (en) 2012-06-28 2014-04-10 Ansun Biopharma, Inc. Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture
WO2014064710A1 (en) 2012-10-22 2014-05-01 Department Of Biotechnology A process for the prepartion of non-viral vector for delivery of nucleic acids by mucosal route
KR20150132131A (ko) 2013-02-05 2015-11-25 1글로브 헬스 인스티튜트 엘엘씨 약물 전달 담체로서 생체분해가능하고 임상적으로 상용가능한 나노입자
MX354474B (es) 2013-03-15 2018-03-07 Laboratory Skin Care Inc Composiciones de agente activo resveratrol particuladas, secas y finas y formulaciones topicas que incluyen las mismas.
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
SG11201609954VA (en) * 2014-05-30 2016-12-29 Abbvie Deutschland Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
AU2015339005B2 (en) 2014-10-31 2020-12-17 Hee Sook Hwang Compositions and methods for bile acid particles
WO2017041053A1 (en) 2015-09-04 2017-03-09 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
US10029031B2 (en) * 2015-10-28 2018-07-24 Warsaw Orthopedic, Inc. Bone void filler having sustained therapeutic agent release
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
US11110064B2 (en) * 2018-12-16 2021-09-07 SRM Institute of Science and Technology Gel formulation for treating diabetic foot ulcer infections
CN111349158B (zh) * 2020-03-06 2022-11-08 西北农林科技大学 一种奶山羊性控精液制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2181426B1 (ru) 1972-04-06 1974-12-20 Pasteur Institut
US4016252A (en) * 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
FR2466991A1 (fr) 1979-10-08 1981-04-17 Pasteur Institut Perfectionnement a la preparation d'allergene
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
DK0465529T3 (da) 1989-03-21 1998-10-05 Vical Inc Ekspression af exogene polynukleotidsekvenser i et hvirveldyr
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5178882A (en) * 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5462751A (en) * 1990-06-22 1995-10-31 The Regeants Of The University Of California Biological and pharmaceutical agents having a nanomeric biodegradable core
US5460830A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Biochemically active agents for chemical catalysis and cell receptor activation
US5306508A (en) * 1990-06-22 1994-04-26 The Regents Of The University Of California Red blood cell surrogate
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5219577A (en) * 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
US5464634A (en) * 1990-06-22 1995-11-07 The Regents Of The University Of California Red blood cell surrogate
JPH05238950A (ja) * 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性ｖｉｐ製剤
ES2242954T3 (es) 1992-03-11 2005-11-16 Powderject Vaccines, Inc. Vacuna genetica para el virus de la inmunodeficiencia.
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5364838A (en) * 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5456986A (en) * 1993-06-30 1995-10-10 Carnegie Mellon University Magnetic metal or metal carbide nanoparticles and a process for forming same
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
US5484720A (en) * 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US8333996B2 (en) 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5648097A (en) * 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US5695617A (en) * 1995-11-22 1997-12-09 Dow Corning Corporation Silicon nanoparticles
AU722326B2 (en) 1997-02-14 2000-07-27 Merck & Co., Inc. Polynucleotide vaccine formulations
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
EP2481401A1 (en) * 1999-01-18 2012-08-01 LG Life Sciences, Ltd. Lipophilic microparticles containing a protein drug or antigen and formulation comprising same
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
ES2228467T3 (es) 1999-02-03 2005-04-16 Biosante Pharmaceuticals, Inc. Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso.
US20020068090A1 (en) * 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
US20020054914A1 (en) 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US6183803B1 (en) * 1999-06-11 2001-02-06 Biosante Pharmaceuticals, Inc. Method for processing milk
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods

Also Published As

Publication number Publication date
ES2344303T3 (es) 2010-08-24
KR20070002014A (ko) 2007-01-04
MXPA06009222A (es) 2007-03-08
JP2007522228A (ja) 2007-08-09
EP1720520A2 (en) 2006-11-15
CN1993113B (zh) 2010-12-08
CN1993113A (zh) 2007-07-04
DE602005021756D1 (de) 2010-07-22
WO2005084637A2 (en) 2005-09-15
WO2005084637A3 (en) 2006-11-02
BRPI0507680A (pt) 2007-07-17
US20050234114A1 (en) 2005-10-20
AU2005219372A1 (en) 2005-09-15
CA2555921A1 (en) 2005-09-15
JP5103022B2 (ja) 2012-12-19
US7651694B2 (en) 2010-01-26
EP1720520B1 (en) 2010-06-09
ATE470433T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
RU2006132735A (ru) Терапевтические частицы фосфата кальция и способы их получения и применения
JP2007522228A5 (ru)
Jiang et al. Nanoformulation of brain‐derived neurotrophic factor with target receptor‐triggered‐release in the central nervous system
DE69735496T2 (de) Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Gene involviert
JP5841708B2 (ja) 表面被覆微粒子の医薬組成物
DE19627392A1 (de) Medikament zur Verabreichung durch die Nase
JPS62255435A (ja) 安定性タンパク質及びタンパク質の安定化法
JP2011519867A5 (ru)
Kalia et al. Rapidly adapting pulmonary receptor afferents: I. Arborization in the nucleus of the tractus solitarius
DE60121355T2 (de) Absorptionsverbesserer
JPH05345727A (ja) イオントフォレーシスによる送達のための分子
WO2008094710A2 (en) Diatom device
Zhang et al. Magnetic chitosan hydrogel induces neuronal differentiation of neural stem cells by activating RAS-dependent signal cascade
Liu et al. Chrysanthemum sporopollenin: A novel vaccine delivery system for nasal mucosal immunity
CN105232463A (zh) 一种具有人肺组织主动靶向性的甲强龙免疫纳米脂质体及其制备方法
DE60017783T2 (de) Biomolekularer komplex,gebildet aus hyaluronsäure und einem biomolekül, herstellungsverfahren dafür und deren therapeutische verwendung
JP2012517430A (ja) 外部からの合図によるオンデマンドで可逆的な薬物放出
JPWO2014157606A1 (ja) 架橋された疎水化多糖ナノゲル粒子とその製造方法
JPH06510752A (ja) アレルギー治療のためのｐ物質の使用方法
Gasperin-Bulbarela et al. Ca-alginate-pegma hydrogels for in situ delivery of tgf-β neutralizing antibodies in a mouse model of wound healing
WO2005112975A1 (de) Verwendung von histonen zur frühdiagnose und/oder präventivtherapie virusinfizierter lebender zellen und ein biochip zur durchführung der diagnose
Xu et al. Enhancement of intranasal mucosal immunization of mucosal vaccines by ultrasonic treatment
JP5628466B2 (ja) 変性疾患または自己免疫疾患治療用、および／または免疫調節性物質としての水溶液
Li et al. Metal–Organic Framework and Hydrogel Based Strategy as a Universal First-Aid Treatment of Three Different Typical Snake Bites
DE69728769T2 (de) Polymerzusammensetzung zur oralen administration von peptiden und proteinen